SecBot SecBot
PRESS-RELEASE ·Filed Mar 20, 2026

PHVS

Pharvaris N.V.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Investors should monitor the upcoming Phase 3 CHAPTER-3 topline data in Q3 2026 as the next major catalyst; successful results could drive significant upside given the lack of oral options in HAE and strong Phase 2/3 signals to date.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.00
T+0 close · Mar 20, 2026 · via day close
Latest settled
+21.31%
T+60 · $31.54
Vs SPY
+6.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 20 $26.00entry
  2. T+1 · 8mo ago −1.15%α −2.26% · $25.70
  3. T+5 · 8mo ago +5.19%α +7.34% · $27.35
  4. T+20 · 7mo ago +11.42%α +2.10% · $28.97
  5. T+60 · 5mo ago +21.31%α +6.89% · $31.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials in The Lancet Haematology, showing deucrictibant's efficacy and safety as both a prophylactic and on-demand oral treatment for hereditary angioedema (HAE). The results support its potential as a first-in-class oral B2 receptor antagonist for end-to-end HAE management, with Phase 3 topline data expected in Q3 2026.

Key Facts

  • Phase 2 CHAPTER-1 trial showed statistically significant reduction in HAE attack frequency with deucrictibant for prophylaxis.
  • Phase 2 RAPIDe-1 trial demonstrated statistically significant reduction in attack severity and faster symptom relief for on-demand treatment.
  • Deucrictibant is an oral bradykinin B2 receptor antagonist, positioning it as a potential first-in-class oral therapy for both prevention and acute treatment of HAE.
  • Topline data from pivotal Phase 3 RAPIDe-3 trial already confirmed faster symptom relief and single-capsule resolution in most attacks.
  • Marketing authorization applications for deucrictibant immediate-release capsule are being prepared, with NDA submission expected in first half of 2026.
  • Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland.

Financial Impact

Potential blockbuster revenue if approved, given deucrictibant's dual indication and oral convenience in a chronic, high-cost rare disease market.

revenuevaluationmarketCap

Risk Factors

  • Phase 3 data may not replicate Phase 2 results, particularly in larger, more diverse populations.
  • Regulatory delays or rejections despite strong data, especially given the novelty of the oral B2 antagonist mechanism.
  • Competition from existing injectable therapies and emerging oral kallikrein inhibitors.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3259646

Track record

51 reports on PHVS

Performance horizon

14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 20, 2026